Galamb Ádám, Benczik Márta, Zinner Balázs, Vígh Eszter, Baghy Kornélia, Jeney Csaba, Kiss András, Lendvai Gábor, Sobel Gábor
2nd Department of Obstetrics and Gynecology, Semmelweis University, Üllői út 78/a, 1082, Budapest, Hungary.
Pathol Oncol Res. 2015 Jul;21(3):503-8. doi: 10.1007/s12253-014-9871-x. Epub 2015 Jan 20.
Data discussed in recent reviews demonstrated that dysregulation of microRNA (miRNA) expression profiles occurs during cervical carcinogenesis and characteristic up- or downregulation of certain miRNAs might be used as biomarkers. The majority of altered miRNAs, however were found to be inconsistent upon comparison with cancerous and normal cervical epithelia in the discussed studies due to several reasons. The results obtained in this present review suggest the need for further investigations on miRNAs on larger sample sizes in order to indicate sensitivity and specificity by means of well defined, "unified" methods. In addition, obtaining further data on the clinical course and outcome of patients in comparison to the dysregulation of miRNA expression profile could turn miRNAs into prognostic and/or progression markers. Inhibition of overexpressed miRNAs, as suggested by some authors, might even serve as target for cancer therapy.
近期综述中讨论的数据表明，在宫颈癌发生过程中会出现微小RNA（miRNA）表达谱的失调，某些miRNA的特征性上调或下调可能用作生物标志物。然而，由于多种原因，在所讨论的研究中，与癌性和正常宫颈上皮相比，大多数改变的miRNA并不一致。本综述获得的结果表明，需要对更大样本量的miRNA进行进一步研究，以便通过明确的“统一”方法来表明敏感性和特异性。此外，与miRNA表达谱失调相比，获取更多关于患者临床病程和结局的数据可能会使miRNA成为预后和/或进展标志物。正如一些作者所建议的，抑制过表达的miRNA甚至可能成为癌症治疗的靶点。
